Keywords: سرطان پروستات متاستاتیک; CT; computed tomography; MCA; middle cerebral artery; ND; not determined; NP; not performed; OSH; outside hospital; SDH; subdural hematoma; SMH; Strong Memorial Hospital; STR; subtotal resection; Subdural hematoma; Mimicking; Prostate carcinoma metastasis
مقالات ISI سرطان پروستات متاستاتیک (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: سرطان پروستات متاستاتیک; Prostate cancer; Metastatic prostate cancer; Pulmonary metastases;
Keywords: سرطان پروستات متاستاتیک; Castration resistance; De novo metastatic disease; Metastatic prostate cancer; Prostate specific antigen; Treatment;
Keywords: سرطان پروستات متاستاتیک; Prostate; Prostate cancer; Multimodal therapy; Metastatic prostate cancer; Treatment;
Keywords: سرطان پروستات متاستاتیک; Bone pain; Communication; International; Metastatic prostate cancer; Pain;
Keywords: سرطان پروستات متاستاتیک; Metastatic prostate cancer; Locally advanced prostate cancer; Hormone-naïve; Docetaxel; Abiraterone; Androgen deprivation therapy;
Keywords: سرطان پروستات متاستاتیک; Competing-risks analyses; Metastatic prostate cancer; Other-cause mortality; SEER Program; Sites of metastases;
Keywords: سرطان پروستات متاستاتیک; PC; prostate cancer; mPC; metastatic prostate cancer; ADT; androgen deprivation therapy; CRPC; castration resistant prostate cancer; mCRPC; metastatic CRPC; SNP; single nucleotide polymorphism; CNV; copy number variation; AR; androgen receptor; CTC; circu
Keywords: سرطان پروستات متاستاتیک; Abiraterone acetate; Androgen deprivation therapy; Castration-resistant prostate cancer; Metastatic prostate cancer; Patient reported outcomes;
Keywords: سرطان پروستات متاستاتیک; Metastatic prostate cancer; Costs and cost analysis; Health expenditures; Economics; Pharmaceutical;
Keywords: سرطان پروستات متاستاتیک; Metastatic prostate cancer; Radical prostatectomy; Surgery; Safety; Perioperative outcomes;
Keywords: سرطان پروستات متاستاتیک; Metastatic prostate cancer; Definitive treatments of the primary tumour; Local radiotherapy
Keywords: سرطان پروستات متاستاتیک; bone metastasis; bone surgery; metastatic prostate cancer; opioid use; pain radiation; skeletal-related event;
Keywords: سرطان پروستات متاستاتیک; Cancer specific survival; Metastatic prostate cancer; Obesity
Keywords: سرطان پروستات متاستاتیک; Denosumab; Hypocalcemia; Metastatic prostate cancer; Osteoclast; RANKL; Skeletal-related event;
Keywords: سرطان پروستات متاستاتیک; Metastatic prostate cancer; Overall survival; Prostate cancer; Androgen deprivation therapy; Site of metastases; Number of metastases;
Keywords: سرطان پروستات متاستاتیک; Metastatic prostate cancer; Castration-resistant; Chemotherapy; Abiraterone; Elderly; Frailty; Activities of daily living; Physical performance; Falls; Quality of life
Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer
Keywords: سرطان پروستات متاستاتیک; Abiraterone; HSD3B1; Metastatic prostate cancer; Predictive biomarker;
Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial
Keywords: سرطان پروستات متاستاتیک; Androgen-receptor axis inhibitors; Chemotherapy; GETUG-AFU 15 trial; Metastatic prostate cancer;
Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases
Keywords: سرطان پروستات متاستاتیک; Androgen deprivation; Surgery; Metastatic prostate cancer; LHRH-analogues; Continence;
Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies
Keywords: سرطان پروستات متاستاتیک; Prostate cancer; Metastatic castrate naive prostate cancer; Metastatic prostate cancer; High volume; Low volume; Volume disease; Androgen deprivation therapy; Docetaxel; Chemotherapy;
ACR Appropriateness Criteria® Post-treatment Follow-up Prostate Cancer
Keywords: سرطان پروستات متاستاتیک; Appropriateness Criteria; Appropriate Use Criteria; AUC; Choline and fluciclovine PET; Metastatic prostate cancer; MRI; Prostate cancer; Recurrent prostate cancer;
Original ResearchQ-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial
Keywords: سرطان پروستات متاستاتیک; Q-TWiST; Metastatic prostate cancer; Docetaxel; Quality-adjusted survival;
Original ResearchImproved survival for patients with de novo metastatic prostate cancer in the last 20 years
Keywords: سرطان پروستات متاستاتیک; Prostate cancer; Metastatic prostate cancer; Endocrine therapy; Overall survival; Cancer-specific survival; Relative survival;
Correlation of PSMA-Targeted 18F-DCFPyL PET/CT Findings With Immunohistochemical and Genomic Data in a Patient With Metastatic Neuroendocrine Prostate Cancer
Keywords: سرطان پروستات متاستاتیک; Immunohistochemistry (IHC); Metastatic prostate cancer; Neuroendocrine prostate cancer; Positron emission tomography/computed tomography (PET/CT) imaging; Prostate-specific membrane antigen;
Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer
Keywords: سرطان پروستات متاستاتیک; SChLAP1; Metastatic prostate cancer; long noncoding RNA; In situ hybridization; Lethal prostate cancer;
Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels
Keywords: سرطان پروستات متاستاتیک; Prostate cancer; SLC18A2; Diagnosis; Prognosis; Biomarkers; AN; Adjacent normal; BPH; Benign prostatic hyperplasia; CRPC; Castration-resistant prostate cancer; PIN; Prostate intraepithelial neoplasia; MPC; Metastatic prostate cancer; RP; Radical prostatec
Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells
Keywords: سرطان پروستات متاستاتیک; AR-V7; Androgen receptor; Cabazitaxel; Castration-resistant prostate cancer; CellSearch; Circulating tumor cells; Metastatic prostate cancer
Prise en charge des cancers de la prostate métastatiques hormonosensibles (CPMHS)
Keywords: سرطان پروستات متاستاتیک; Cancer de la prostate; Cancer de la prostate métastatique; Hormonosensible; Sensible à la castration; M1; Docétaxel; Prostate cancer; Metastatic prostate cancer; Castration-sensitive; Non-castrate; M1; Docetaxel;
Locoregional symptoms in patients with de novo metastatic prostate cancer: Morbidity, management, and disease outcome
Keywords: سرطان پروستات متاستاتیک; Metastatic prostate cancer; Locoregional treatment; Locoregional symptoms; Outcomes assessment; Morbidity;
Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study
Keywords: سرطان پروستات متاستاتیک; Metastatic prostate cancer; Radical prostatectomy; Brachytherapy; Outcomes assessment;
A rat model of metastatic spinal cord compression using human prostate adenocarcinoma: histopathological and functional analysis
Keywords: سرطان پروستات متاستاتیک; Metastatic prostate cancer; Spine tumor; Spinal metastasis; Animal model; Animal gait locomotion
A Phase II Trial of Temsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer
Keywords: سرطان پروستات متاستاتیک; Castration-resistant; Circulating tumor cells; Epithelial-mesenchymal transition; Metastatic prostate cancer; mTOR; N-cadherin; Prostate-specific antigen; Temsirolimus
A Case Report of Putative Autoimmunity to Prostate Cancer After Immune-Mediated Rejection of Melanoma Through a Shared Tumor Antigen
Keywords: سرطان پروستات متاستاتیک; Metastatic prostate cancer; PSA; PSMA; Autoimmunity;
Castration-resistant prostate cancer: Where are we going?
Keywords: سرطان پروستات متاستاتیک; Metastatic prostate cancer; Castration-resistant prostate cancer; Hormonal therapies; Progression; Cabazitaxel; Cáncer de próstata metastásico; Cáncer de próstata resistente a castración; Terapias hormonales; Progresión; Cabazitaxel;
Prognostic factors in metastatic prostate cancer
Keywords: سرطان پروستات متاستاتیک; Metastatic prostate cancer; Prostate specific antigen; Gleason score; Prognostic factor
Metastatic castrate-resistant prostate cancer: New landscape, new challenges
Keywords: سرطان پروستات متاستاتیک; Prostate cancer; CRPC; Chemotherapy; Metastatic prostate cancer
Phase I trial with a combination of docetaxel and 153Sm-lexidronam in patients with castration-resistant metastatic prostate cancer
Keywords: سرطان پروستات متاستاتیک; 153Sm-lexidronam; Metastatic prostate cancer; Docetaxel; Phase I
Comparison of Circulating MicroRNA 141 to Circulating Tumor Cells, Lactate Dehydrogenase, and Prostate-Specific Antigen for Determining Treatment Response in Patients With Metastatic Prostate Cancer
Keywords: سرطان پروستات متاستاتیک; Circulating tumor cells; Lactate dehydrogenase; Metastatic prostate cancer; microRNA; Prostate-specific antigen
Introducing Vantas: The First Once-Yearly Luteinising Hormone-Releasing Hormone Agonist
Keywords: سرطان پروستات متاستاتیک; Buserelin; Goserelin; Histrelin; Implant; Leuprolide; Metastatic prostate cancer; Triptorelin; Vantas
Long-Term Hormonal Therapy: Who Would Benefit?
Keywords: سرطان پروستات متاستاتیک; Adjuvant; Androgen deprivation; Metastatic prostate cancer; Orchiectomy; Palliative; Prostatectomy; Survival
Prostate adenocarcinoma manifesting as generalized lymphadenopathy
Keywords: سرطان پروستات متاستاتیک; Prostate adenocarcinoma; Metastatic prostate cancer; Generalized lymphadenopathy; Prostate-specific antigen
Leptomeningeal carcinomatosis in a patient with metastatic prostate cancer: case report and literature review
Keywords: سرطان پروستات متاستاتیک; CNS, central nervous system; CSF, cerebrospinal fluid; CT, computed tomography; MRI, magnetic resonance imaging; PSA, prostate-specific antigenLeptomeningeal metastases; Metastatic prostate cancer; PSA in the CNS in prostate cancer
Role of Luteinising Hormone Releasing Hormone (LHRH) Agonists and Hormonal Treatment in the Management of Prostate Cancer
Keywords: سرطان پروستات متاستاتیک; Prostate cancer; LHRH agonists; Adjuvant therapy; Neoadjuvant therapy; Early prostate cancer; Advanced prostate cancer; Metastatic prostate cancer; Biochemical recurrence; Review;